Cancer Treatment Reviews

Article	Citations
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review	289
Editorial Board	191
Comparison of the pathological complete response between immunohistochemistry HER2 (3 + ) and HER2 (2 + )/ISH + Early-stage breast cancer: a systematic review and meta-analysis	155
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives	126
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty	107
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer	103
Interleukin-8: a tumor-agnostic biomarker integrating cancer biology and host response across solid tumors	103
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer	99
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in	91
The interplay of clonal hematopoiesis and cancer: Clinical implications in oncology	89
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis	87
Transformation from EGFR-mutant lung adenocarcinoma to small-cell lung cancer: from clonal evolution to lineage reprogramming	85
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer	78
Editorial Board	76
Revisiting patient preference in resectable and irradiable stage III NSCLC in the immunotherapy era	73
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.	68
Optimizing care in early phase cancer trials: The role of palliative care	66
Progress toward personalized management of stage II/III triple negative breast cancer	63
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches	62
Opportunities and challenges for non–small cell lung cancer brain metastases in the immunotherapy era	61
Proton therapy in breast cancer: bridging medical and radiation oncology	60
De-escalation strategies with targeted therapies in non-small cell lung cancer	59
Emerging mechanisms of triple-negative breast cancer radioresistance: Interplay between cancer cell mechanisms and the tumor immune microenvironment	59
Surgical tumor volume reduction in patients with brain metastases: A systematic review and meta-analysis	59
If it’s a target, it’s a pan-cancer target: Tissue is not the issue	58

FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma	57
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?	55
Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications	55
CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation	55
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?	54
Uncertainties and controversies in axillary management of patients with breast cancer	54
Editorial Board	52
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials	52
Editorial Board	52
Circulating tumor DNA in breast cancer: From technological foundation to clinical implementation	51
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC	51
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck	51
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes	50
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations	49
Combining antibody-drug conjugates with immune checkpoint inhibitors: A new paradigm for breast cancer therapy	48
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment	47
Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?	46
Editorial Board	45
Management of multifocal and metastatic retroperitoneal sarcoma: an updated consensus approach from the transatlantic australasian retroperitoneal sarcoma working group (TARPSWG)	43
Corrigendum to “The importance of education and training in neuroendocrine neoplasms: challenges and opportunities for multidisciplinary management”. [Cancer Treat. Rev. 139 (2025) 102998]	43
The immunogram of inflammatory breast cancer	42
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review	42
Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis	42
Extracellular vesicles and the “six Rs” in radiotherapy	41
Overview of BH3 mimetics in ovarian cancer	41
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design	41
HER-2 directed therapies across gastrointestinal tract cancers – A new frontier	40
The role of the 21-gene assay in the neoadjuvant setting for hormone receptor-positive HER2-negative breast cancer: Impact on systemic and surgical treatment decisions	40
Managing strategies of chemotherapy and radiotherapy-induced oral mucositis	39
Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada	38
Expanding the therapeutic Frontier: Liver transplantation for unresectable colorectal liver metastases	36
Editorial Board	36
Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma	36
How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers	35
Long-term surveillance recommendations for young adult cancer survivors	35
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)	34
Clinical efficacy and immunological aspects of neoadjuvant and perioperative therapy in resectable head and neck carcinoma	34
Editorial Board	33
Deciphering primary acinic cell carcinoma of the Breast: Insights from a comprehensive case series and Systematic review	33
Optimizing outcomes and personalizing care with targeted agents in advanced cholangiocarcinoma	33
Assessing lung function in women treated for breast cancer with radiotherapy. A comprehensive systematic review and meta-analysis	33
Angiogenesis and thymic epithelial tumors: from preclinical insights to different therapeutic lines and combination strategies	33
Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review	33
Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer	32
Immunocytokines in cancer treatment: A systematic review	32
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer	32
Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+/HER2– advanced breast cancer: An updated systematic review and meta-analysis of randomized controlled trials	32
Agnostic drug development revisited	32
Malignant ascites: Current therapy options and treatment prospects	32
Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review	32

Mechanisms and biomarkers for musculoskeletal signs and symptoms in patients treated with aromatase inhibitors: A comprehensive systematic review	32
Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life	30
Editorial Board	30
Bone complications of cancer treatment	30
Editorial Board	30
Corrigendum to “T-cell engager toxicity in clinical phase trials; A systematic review and meta-analysis”. [Cancer Treat Rev. 139 (2025) 102991. doi: 10.1016/j.ctrv.2025.102991]	29
Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review	29
Effectiveness of immune checkpoint inhibitor therapy in thyroid cancer: A systematic review	29
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers	29
Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review	29
Genomic distinctions in adolescent and young adult cancer: A comprehensive review	29
Prognostic role of postoperative circulating tumor DNA in metastatic colorectal cancer treated with curative intent: A systematic review and meta-analysis	28
Local control strategies for management of NSCLC with oligoprogressive disease	28
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review	28
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis	28
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?	27
Vinorelbine and low-dose cyclophosphamide as maintenance therapy in the treatment of Ewing sarcoma rationale for the international INTER-EWING-1 trial for Ewing sarcoma patients	27
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review	27
Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes	27
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges	27
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?	27
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification	27
Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives	27
Does the benefit of neoadjuvant chemotherapy at six months predict long-term outcomes in colon or rectal cancer? A meta-analysis of randomised studies	26
Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic revie	26
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project	26
Early onset pancreatic Cancer: epidemiology, molecular features, and clinical outcomes	25
Pharmacotherapy for leptomeningeal disease in breast cancer	25
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer	25
Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312]	25
Management of infections in the outpatient care of patients with cancer	25
Patient-reported outcome measure to implement routine assessment of cancer survivors’ unmet needs: An overview of reviews and COSMIN analysis	25
Review: Targeting EZH2 in neuroblastoma	24
Strategies for improving detection of circulating tumor DNA using next generation sequencing	24
Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases	24
Engineering strategies to optimise adoptive cell therapy in ovarian cancer	24
Evolving immunotherapeutic solutions for triple-negative breast carcinoma	24
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis	24
Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies	24
Editorial Board	23
Identification of the PROMs used to assess ICI toxicities and HRQoL in patients receiving immune checkpoint inhibitor treatment in cancer care and their suitability: A systematic review	23
Editorial Board	23
Ex vivo drug screening on patient-derived tumor material to advance functional precision in oncology: an overview on current approaches and unresolved challenges	23
Editorial Board	22
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis	22
Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment	22
Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy	21
Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis	21
Editorial Board	21
Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progression	21
Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives	21
From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia	21
A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments	21
Diagnostic utility of urinary cell-free DNA in non-urothelial cancer: a systematic review, meta-analysis, & network meta-analysis	21
Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non–small cell lung cancer	21
Selecting systemic treatment for metastatic neuroendocrine tumors of the lung—current evidence and clinical implications	21
Erratum to “Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review”. [Cancer Treat. Rev. 140 (2025) 103024]	21
Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review	21
Novel therapies targeting delta-like ligand 3 (DLL3) in pulmonary and gastroenteropancreatic neuroendocrine carcinomas	20
Comparative review of KEYNOTE-689 and NIVOPOSTOP trials and their impact on perioperative immunotherapy in locally advanced head and neck cancer	20
Editorial Board	20
Advances in treatment strategies for low-grade serous ovarian cancer	20
Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma	20
Multimodality treatment of primary cardiac angiosarcoma: A systematic literature review	20
Considerations regarding a network meta-analysis of targeted therapies for BRAF-mutant unresectable or metastatic melanoma	20
An umbrella review of systematic reviews on the diagnostic and prognostic utility of circulating tumor DNA and MicroRNA in colorectal cancer	19
Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?	19
Clinical recommendations for treatment of localized angiosarcoma: A consensus paper by the Italian Sarcoma Group	19
Corrigendum to “Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)” [Cancer Treatment Reviews 123 (2024) 102672]	19
Management approaches for recurrent or metastatic head and neck squamous cell carcinoma after anti-PD-1/PD-L1 immunotherapy	19
A systematic review of eHealth technologies for breast cancer supportive care	19
Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)	19
Challenges to genetic testing for germline mutations associated with breast cancer among African Americans	19
MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action	18
Corrigendum to “PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives” [Cancer Treat. Rev. 131 (2024) 102850]	18
BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives	18
Clearer Horizons: The latest advances in clear cell ovarian cancer treatment	18
Re-challenge strategies in neuroendocrine tumours: adding another arrow in the quiver?	18
Exercise in patients with metastatic prostate cancer: A comprehensive review	18
Germline TP53 pathogenic variants and breast cancer: A narrative review	18

Desmoid-type fibromatosis: Current therapeutic strategies and future perspectives	17
PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer	17
Clinical course and treatment outcomes in solid-basaloid adenoid cystic carcinoma of the breast: A systematic review and case report	17
Harnessing epigenetics: Genome-wide DNA methylation assay for colorectal cancer therapy	17
CAR-T cell therapy for breast cancer: Current status and future perspective	17
Editorial Board	17
Targeting key epigenetic regulators in solid tumors: focus on EZH2, PRMT5, and BET inhibitors	17
First-line treatment of locally advanced cervical carcinoma: An updated systematic review and Bayesian network meta-analysis	17
Antibody-drug conjugates for hepato-pancreato-biliary malignancies: “Magic bullets” to the rescue?	17
Local administration of immunotherapy for patients with skin cancer: A systematic review	17
The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review	17
T-cell engager toxicity in clinical phase trials; A systematic review and meta-analysis	17
Functioning neuroendocrine tumors (NET): Minimum requirements for a NET specialist	17
Acquired resistance mechanisms to osimertinib: The constant battle	16
Editorial Board	16
Biomarker-guided immunotherapy in gastric cancer: current insights and future perspectives	16
The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice	16
Individualizing first-line treatment for advanced urothelial carcinoma: A favorable dilemma for patients and physicians	16
Current controversies in the use of Oncotype DX in early breast cancer	15
Editorial Board	15
Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis	15
Treatment decision-making factors and sequencing in recurrent and/or metastatic squamous cell carcinoma of the head and neck	15
Editorial Board	15
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing	14
Antibody based therapies in Hodgkin lymphoma	14
Insights into RAS-driven melanoma and its therapeutic implications	14
Editorial Board	14
Neoadjuvant therapy and translational biomarkers for metastatic risk in early breast cancer	14
The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer	14
Enhancing radiotherapy techniques for Triple-Negative breast cancer treatment	14
Editorial Board	14
Rethinking endpoints for the watch-and-wait strategy in rectal cancer	14
Comprehensive genomic profiling in solid tumours: Navigating promise, challenges, and pathways to clinical integration	14
Beyond HER2: Targeting the ErbB receptor family in breast cancer	14
Chimeric antigen receptor NK cells for breast cancer immunotherapy	14
Editorial Board	14
European expert panel consensus on the clinical management of BRAF-mutant metastatic colorectal cancer	14
Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer	14
Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group	14
Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck	14
Advancements in platinum chemotherapy for metastatic castration-resistant prostate cancer: Insights and perspectives	13
Molecular aspects of brain metastases in breast cancer	13
Response to “Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into ac	13
Immunotherapy-based combinations in metastatic NSCLC	13
Primary tumor and metastasis-directed treatment for oligometastatic prostate cancer: An umbrella review of meta-analyses	13
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy	13
Editorial Board	13
Bone metastases in NSCLC: Modern paradigms in management and supportive care	13
Primary mediastinal large B-cell Lymphoma: Biological features, clinical characteristics and current treatment strategies	13
Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer	13
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?	13
Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development	13
Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody–drug conjugates	13
Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma	13
Evasion of apoptosis and treatment resistance in squamous cell carcinoma of the head and neck	12
Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation	12
Physical activity reduces all-cause mortality in patients with cancer: a systematic review and meta-analysis of randomized controlled trials	12
Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors	12
Editorial Board	12
Implications of bone metastasis on response to systemic therapy in patients with advanced renal cell carcinoma: A systematic literature review	12
Phase III placebo-controlled oncology trials in the last decade: evolution, methodological foundations, and clinical impact	12
Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges	12
Immunotherapy with anti-PD-1 or PD-L1 in advanced ovarian cancer: A meta-analysis of randomized trials	12
Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma	12
Corrigendum to “Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis” [Cancer Treat. Rev. 125 (2024) 102704]	12
Long road towards effective HER3 targeting in breast cancer	12
Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials	12
Intermittent fasting and its impact on toxicities, symptoms and quality of life in patients on active cancer treatment	12
Editorial Board	11
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis	11
Targeted precision Strike in Extensive-Stage small cell lung Cancer: Current advances and future Perspectives for Antibody–Drug conjugates	11
Pathologic complete response in patients with localized soft tissue sarcoma treated with neoadjuvant therapy and its correlation with clinical outcomes: A systematic review	11
The present and the future of immunotherapy in hepatocellular carcinoma and biliary tract cancers	11
First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States	11
Targeted therapeutic strategies in rare subtypes of pancreatic cancer: Histology, molecular profiles, and emerging opportunities	11
Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials	11
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treat. Rev.	11
Induction chemotherapy followed by chemoradiotherapy for locally advanced cervical cancer: A systematic review and meta-analysis	11
Evolving therapeutics and ensuing cardiotoxicities in triple-negative breast cancer	11
Shaping the tumor immune microenvironment of SCLC: Mechanisms, and opportunities for immunotherapy	11
Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists	11
The 5-WS of targeting DNA-damage repair (DDR) pathways in prostate cancer	11
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer	10
Systematic literature review of intravenous versus subcutaneous administration of oncology therapies: A clinical, economic and patient perspective	10
Editorial Board	10
NTRK gene fusion testing and management in lung cancer	10
Sequencing antibody–drug conjugates in metastatic breast cancer: A systematic review	10
Toxicities following CAR-T therapy for hematological malignancies	10
Comparative analysis of international guidelines on the management of advanced non-functioning well-differentiated pancreatic neuroendocrine tumors	10
Long and short-term efficacy and safety comparison of nab-paclitaxel versus paclitaxel combined with trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer: A systematic r	10
Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma	10
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer	10
Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma	10
Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome	10
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials	10